Simponi Aria (golimumab for infusion)
Effective 06/01/2021

Plan	☐ MassHealth ☒ MassHealth (PUF) ☐Commercial/Exchange	**Program Type**	☒ Prior Authorization ☒ Quantity Limit ☐ Step Therapy
Benefit	☒ Pharmacy Benefit ☒ Medical Benefit (NLX)		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy when filled through the pharmacy benefit.		
Contact Information	**Specialty Medications**		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Simponi Aria is a tumor necrosis factor (TNF) blocker indicated for:

- Treatment of moderately to severely active Rheumatoid Arthritis (RA)
- Treatment of ankylosing spondylitis
- Treatment of psoriatic arthritis (PsA)
- Treatment of moderate to severe polyarticular juvenile idiopathic arthritis (pJIA)

Coverage Guidelines

Authorization may be reviewed on a case by case basis for members new to AllWays Health Partners who are currently receiving treatment with Simponi Aria excluding w hen the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

Moderate to Severe Rheumatoid Arthritis (RA) and Polyarticular Juvenile Idiopathic Arthritis (pJIA)

Prescriber provides documentation of **ALL** of the following:

1. Appropriate diagnosis
2. **ONE** of the following:
    a. Paid claims or physician documented inadequate response or adverse reaction to at least ONE traditional DMARD or contraindication to traditional DMARDs
    b. Paid claims or physician documented inadequate response or adverse reaction to ONE biologic DMARD that is FDA-approved for the requested indication
3. Dosing is appropriate

4. Prescriber provides clinical rationale for use of Simponi Aria instead of Enbrel® and Humira®

Psoriatic Arthritis (PsA)
Prescriber provides documentation of **ALL** of the following:
1. Appropriate diagnosis
2. Appropriate dosing
3. Prescriber provides clinical rationale for use of Simponi Aria instead of Enbrel® and Humira®

NOTE: DMARD trial is not required in members with active ankylosing spondylitis or psoriatic arthritis with axial (spine) involvement (including sacroiliitis) whose condition is not sufficiently controlled with NSAIDs.

Ankylosing spondylitis (AS)
Prescriber provides documentation of **ALL** of the following:
1. Appropriate diagnosis
2. Paid claims or physician documented inadequate response or adverse reaction to **TWO** NSAIDs or contraindication to **ALL** NSAIDs
3. Appropriate dosing (see appendix A)
4. Prescriber provides clinical rationale for use of Simponi Aria instead of Enbrel® and Humira®

Continuation of Therapy
Reauthorization requires physician documentation of continuation of therapy, positive response to therapy, FDA approved indication and appropriate dosing.

Limitations
1. Initial approvals will be for 6 months.
2. Reauthorizations will be for 12 months.
3. The following quantity limits apply:

Simponi Aria Solution 50mg	4 units per 8 weeks

Appendix
Appendix A: Dosing

Simponi Aria (golimumab for infusion)	**Rheumatoid arthritis (moderate-severe), Psoriatic arthritis, and Ankylosing spondylitis:** 2 mg/kg IV at weeks 0 and 4, then every 8 weeks in combination with methotrexate

References

1. Simponi Aria (golimumab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; May 2018.
2. Smolen JS, Landewé R, Billsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 0:1-18.
3. SBraun J, Baraliakos X, Hermann KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 2014; 73:1107.
4. Weinblatt ME, Bingham CO 3rd, Mendelsohn AM, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week

2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GOFURTHER trial. Ann Rheum Dis. 2013 Mar; 72(3):381-9

Review History

02/22/10 – Reviewed
04/05/10 – Effective
02/28/11 – Reviewed
02/27/12 – Reviewed
02/25/13 – Reviewed
01/13/14 – Reviewed and revised (Simponi Aria update; 08/26/13 file & plan decision wt-based QL applied to PA)
02/23/15 – Reviewed
02/22/16 – Reviewed
02/27/17 – Reviewed and revised (adopted SGM& ST) in P&T Meeting
03/01/18 – Reviewed (adopted MH RS)
02/20/19 – Reviewed in P&T Meeting
10/21/2020 – Reviewed and Updated; separated out Comm/Exch vs. MassHealth. Matched MassHealth Preferred Unified Formulary for implementation 1/1/2021
03/17/2021 – Reviewed and Updated; Added moderate to severe polyarticular juvenile idiopathic arthritis (pJIA) to criteria. Effective 06/01/2021.

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.